At its 2026 interim results briefing today, Zhaoyan New Drug said a recovery in
domestic innovative drug financing and BD/licensing activity has sharply lifted
demand for non‑human primate (NHP) laboratory models. Breeding rates are broadly
stable and industry supply elasticity is low, preventing rapid capacity
expansion; consequently domestic NHP supply is tight and prices have risen.